Whether it will decrease to a threshold where you just can't recapture them, it's a roll of the dice each time
Tirzepatide, a dual GLP-1 and GIP receptor agonist, slows stomach emptying to reduce hunger and increase fullnessbut this same mechanism often triggers burping, bloating, and gas in the first month of treatment
Hepatic Uncommon (0.1% to 1%): Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) Hypersensitivity Common (1% to 10%): Hypersensitivity reactions (e.g., urticaria, eczema) Postmarketing reports : Anaphylaxis, angioedema Immunologic Very common (10% or more): Anti-drug antibodies (up to 51%) Common (1% to 10%): Neutralizing antibodies Local Common (1% to 10%): Injection site reactions Metabolic Very common (10% or more): Hypoglycemia (up to 19%), decreased appetite (up to 11%) Common (1% to 10%): Hyperglycemia Hypoglycemia (glucose level less than 54 mg/dL) occurred more frequently when this drug was used in combination with a sulfonylurea (up to 13% of patients in a clinical trial)
Online or phone booking
While it is not yet FDA-approved for weight loss, ongoing clinical trials are exploring its potential in this area
